This product is a human monoclonal antibody IgG1, λ targeting Rhesus (Rh) antigen.
Figure 1 Flow cytometric analysis of HEK293 cells expressing recombinantRhAG and RhD antigen.
The human MAbanti-D F5was used to compare RhDantigen expression on hygromycin- and G418-resistant HEK293/RhAG/RhD cells(____) and HEK293/RhD cells (. .). In dot-plot representations, the R2 region wasdefined as a positive region in which no signal was detected with negative controls(mouse IgG1 andhuman anti-K1MAb).
Mouro-Chanteloup, I., D'Ambrosio, A. M., Gane, P., Le Van Kim, C., Raynal, V., Dhermy, D., ... & Colin, Y. (2002). Cell-surface expression of RhD blood group polypeptide is posttranscriptionally regulated by the RhAG glycoprotein. Blood, The Journal of the American Society of Hematology, 100(3), 1038-1047.
Figure 2 Flow cytometric analysis of the enrichment of K562 cells expressingrecombinant RhD antigen by magnetic-bead sorting.
The human MAb anti-D F5was used to compare RhD antigen expression on G418-resistant K562/RhD cellsbefore and after magnetic bead sorting, as described in "Materials and methods."K562/Lu stablyexpressing therecombinant Lu blood groupglycoprotein wasused asnegative control.
Mouro-Chanteloup, I., D'Ambrosio, A. M., Gane, P., Le Van Kim, C., Raynal, V., Dhermy, D., ... & Colin, Y. (2002). Cell-surface expression of RhD blood group polypeptide is posttranscriptionally regulated by the RhAG glycoprotein. Blood, The Journal of the American Society of Hematology, 100(3), 1038-1047.
Gravina, Alessia, et al. "Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression." Nature biotechnology 41.5 (2023): 717-727. https://doi.org/s41587-022-01540-7
The study investigates the protection of cell therapeutics from antibody-mediated killing through the overexpression of CD64. This approach enhances the survival and efficacy of allogeneic cell therapeutics used in cancer therapy and regenerative medicine. The research demonstrates that engineered cells overexpressing CD64 can effectively evade antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), which are primary mechanisms of antibody-mediated rejection.
At Creative Biolabs, we provided several essential reagents for this research. These included the humanized anti-MICA IgG1 antibody (Cat#: TAB-0799CL), the humanized anti-CD52 IgG1 antibody (Cat#: FAMAB-0089WJ), the humanized anti-CD52 IgG1 antibody (Cat#: FAMAB-0014JF), and the hypusine antibody (Cat#: HPAB-0440-YJ). Our products were crucial for the experiments involving antibody-mediated killing assays, enabling the detailed examination of how engineered cells can evade immune detection and destruction. This study highlights the potential of CD64 overexpression to enhance the viability of cell-based therapies, underscoring our commitment to supporting advanced research and innovative therapeutic solutions.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
FAMAB-0089WJ-F(E) | Human Anti-Rh(D) Recombinant Antibody (clone F5); Fab Fragment | ELISA, WB | Human Fab |
There are currently no Customer reviews or questions for FAMAB-0089WJ. Click the button above to contact us or submit your feedback about this product.
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# FAMAB-0089WJ, RRID: AB_3111311)
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.